Eli Lilly financials in line with expectations

28 January 2016

US pharma major Eli Lilly (NYSE: LLY) reported financial results, showing that fourth-quarter 2015 revenue rose 5% to $5.38 billion from $5.12 billion, boosted by increased sales of its diabetes drugs and just beating analysts’ average expectations of $5.32 billion.

Net income rose to $478.4 million, or $0.45 per share, from $428.5 million, or $0.40 per share, a year earlier. Excluding special items, earnings per share were $0.78 cents, in line with the average analyst expectation, according to Thomson Reuters I/B/E/S. The company’s shares were barely changed following market opening.

For the full-year 2015, revenues were up 2% at $19.96 billion, with net income rising 1% to $2.41 billion and earnings per share up 1% to $2.26, or $3.43 excluding items, a rise of 13%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK